Business
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disorders Preclinical data supports the potential of SRK-439
About this update from Scholar Rock Holding Corporation
[{"type":"text","content":"\n\nSRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disorders\n\n\n\nPreclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss\n\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nScholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced a poster presentation at the upcoming Keystone Symposia’s Obesity: Causes and Consequences meeting, to be held February 4 – 6, 2024, in Vancouver, BC, Canada. Scholar Rock will present preclinical data evaluating SRK-439 in combination with GLP-1 receptor agonists in obesity to maintain lean mass and enhance fat mass loss.\n\n\n“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective treatments with rapid implementation for obesity, a recognized global epidemic. However, the weight loss resulting from GLP-1 RA treatment has been shown to be associated with significant loss of lean muscle mass. Retaining muscle mass is critical to overall metabolic health, including improved glucose metabolism, insulin sensitivity, bone density and strength. These data support the potential of SRK-439 to support healthier, safer, and more sustainable weight loss with GLP-1 RA therapy,” said Mo Qatanani, Ph.D., Senior Vice President and Head of Research at Scholar Rock.\n\n\nDetails of the presentation are as follows:\n\n\nTitle: SRK-439, a Selective Anti-Pro and Latent Myostatin Antibody, Maintains Lean Mass and Enhances Fat Mass Loss in Models of Pharmacologically Induced Weight Loss\nPresentation type: Poster presentation\nPresenter: Melissa Fulham, PhD, Senior Scientist II, Scholar Rock\nDate and time: Monday, February 5, 2024, 7:30 PM PST\nLocation: Fairmont Hotel Vancouver, Vancouver, BC, Canada\n\n\nFor conference information, visit https://www.keystonesymposia.org/\n\n\nAbstracts will be viewable to registered attendees 7 days in advance of the conference. The presentation will be made available in the Publications & Posters section of Scholar Rock’s website following the presentation.\n\n\nAbout SRK-439\n\n\nSRK-439 is a novel, preclinical, investigational myostatin inhibitor that ha...